Boston Biomedical, Inc. Highlights Presentations on Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) at ASCO 2018

Boston Biomedical, Inc. Highlights Presentations on Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) at ASCO 2018

CAMBRIDGE, Mass., June 1, 2018 /PRNewswire-USNewswire/ — Boston Biomedical, Inc., an industry leader in the development of novel cancer therapeutics, today announced that it will present new research evaluating investigational compound napabucasin in the treatment of multiple cancers, including metastatic pancreatic adenocarcinoma, advanced